Use of IGF-I or analogues thereof in the prevention of diabetes

Abstract

IGF-I or an analogue thereof is administered to delay the clinical onset of diabetes, to reduce the occurrence of beta cell destruction in a subject having a high risk of developing diabetes, to provide a regulating effect on spleen T cells in a subject having a high risk of developing diabetes, or to reduce the likelihood of the occurrence of clinical diabetes in a subject having a high risk of developing diabetes.

1 . Use of IGF-I or analogues thereof in the manufacture of a medicament useful in the prevention of diabetes.  
     
     
         2 . Use of IGF-I or analogues thereof in the manufacture of a medicament useful in delaying the clinical onset of diabetes.  
     
     
         3 . Use of IGF-I or analogues thereof in the manufacture of a medicament having a protective effect against diabetes.  
     
     
         4 . Use of IGF-I or analogues thereof in the manufacture of a medicament preventing beta cell destruction in subjects that are at high risk of developing diabetes.  
     
     
         5 . Use of IGF-I or analogues thereof in the manufacture of a medicament for regulating T cells in subjects at high risk of developing diabetes.  
     
     
         6 . Method for preventing diabetes by administration of IGF-I or analogues thereof.  
     
     
         7 . Method for delaying the clinical onset of diabetes by administration of IGF4 or analogues thereof.  
     
     
         8 . Method for protecting against diabetes by administration of IGF-I or analogues thereof.  
     
     
         9 . Method for preventing beta cell destruction in subjects which are at high risk of developing diabetes by administration of IGF-I or analogues thereof.  
     
     
         10 . Method for regulating of T cells in subjects which are at high risk of developing diabetes by administration of IGF-I or analogues thereof.